KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allegro Microsystems (ALGM) Asset Writedowns and Impairment (2019 - 2025)

Allegro Microsystems (ALGM) has disclosed Asset Writedowns and Impairment for 7 consecutive years, with $3.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Asset Writedowns and Impairment rose 9.93% to $3.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $8.3 million, a 29.4% increase, with the full-year FY2025 number at $8.5 million, down 5.72% from a year prior.
  • Asset Writedowns and Impairment was $3.0 million for Q4 2025 at Allegro Microsystems, up from $1.1 million in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $5.1 million in Q2 2023 to a low of -$5.7 million in Q1 2023.
  • A 5-year average of $1.4 million and a median of $2.1 million in 2022 define the central range for Asset Writedowns and Impairment.
  • Peak YoY movement for Asset Writedowns and Impairment: plummeted 229.51% in 2022, then surged 538.46% in 2024.
  • Allegro Microsystems' Asset Writedowns and Impairment stood at $348000.0 in 2021, then surged by 87.93% to $654000.0 in 2022, then plummeted by 34.4% to $429000.0 in 2023, then soared by 538.46% to $2.7 million in 2024, then rose by 9.93% to $3.0 million in 2025.
  • Per Business Quant, the three most recent readings for ALGM's Asset Writedowns and Impairment are $3.0 million (Q4 2025), $1.1 million (Q3 2025), and $2.9 million (Q2 2025).